Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial
- PMID: 10520976
- DOI: 10.4088/jcp.v60n0904
Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial
Abstract
Background: We report the results of an open trial of cognitive-behavioral therapy (CBT) using exposure and ritual prevention as an adjunct to serotonin reuptake inhibitors (SRIs) in obsessive-compulsive disorder (OCD). We hypothesized that exposure and ritual prevention would significantly reduce OCD symptoms in patients who remained symptomatic despite an adequate trial of an SRI and enable patients to discontinue their medication.
Method: OCD patients taking an adequate dose of an SRI > or = 12 weeks who remained symptomatic (i.e., a Yale-Brown Obsessive Compulsive Scale [Y-BOCS] score > or = 16) were eligible. While taking a stable dose of an SRI, patients received 17 sessions of exposure and ritual prevention. For the intent-to-treat group, the paired t test was used to compare scores on the Y-BOCS, the National Institute of Mental Health (NIMH) Global OCD scale, the Clinical Global Impressions scale, and the Hamilton Rating Scale for Depression before and after exposure and ritual prevention.
Results: Six of 7 eligible patients entered the study, and 5 completed it. All 6 improved on all OCD measures. The mean +/- SD Y-BOCS score was 23.8 +/- 2.6 prior to exposure and ritual prevention and 12.2 +/- 4.3 after it (p < .001). The mean percentage decrease on the Y-BOCS was 49% (range, 26%-61%). Patients were rated by the therapist and rated themselves as much (N = 4) or very much (N = 2) improved. Blood drug levels did not change in most patients during exposure and ritual prevention; thus, the improvement was attributed to this type of therapy. No patients discontinued their medication.
Conclusion: This open trial suggests that CBT using exposure and ritual prevention can lead to a significant reduction in OCD symptoms in patients who remain symptomatic despite an adequate trial of an SRI.
Similar articles
-
A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder.Am J Psychiatry. 2008 May;165(5):621-30. doi: 10.1176/appi.ajp.2007.07091440. Epub 2008 Mar 3. Am J Psychiatry. 2008. PMID: 18316422 Free PMC article. Clinical Trial.
-
Addition of cognitive-behavioral therapy for nonresponders to medication for obsessive-compulsive disorder: a naturalistic study.J Clin Psychiatry. 2007 Oct;68(10):1552-6. doi: 10.4088/jcp.v68n1013. J Clin Psychiatry. 2007. PMID: 17960971
-
Maintenance of Wellness in Patients With Obsessive-Compulsive Disorder Who Discontinue Medication After Exposure/Response Prevention Augmentation: A Randomized Clinical Trial.JAMA Psychiatry. 2022 Mar 1;79(3):193-200. doi: 10.1001/jamapsychiatry.2021.3997. JAMA Psychiatry. 2022. PMID: 35080598 Free PMC article. Clinical Trial.
-
A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy.Curr Med Chem. 2018;25(41):5647-5661. doi: 10.2174/0929867325666171222163645. Curr Med Chem. 2018. PMID: 29278206
-
Issues in the pharmacological treatment of obsessive-compulsive disorder.Int J Clin Pract. 2007 Jul;61(7):1188-97. doi: 10.1111/j.1742-1241.2007.01356.x. Epub 2007 May 18. Int J Clin Pract. 2007. PMID: 17511795 Review.
Cited by
-
An Atypical and Resistant Case of Obsessive Compulsive Disorder Responding Satisfactorily with an Unusual way of Exposure and Response Prevention Therapy.J Clin Diagn Res. 2016 Mar;10(3):VD03-VD04. doi: 10.7860/JCDR/2016/18633.7481. Epub 2016 Mar 1. J Clin Diagn Res. 2016. PMID: 27134980 Free PMC article.
-
A 2012 evidence-based algorithm for the pharmacotherapy for obsessive-compulsive disorder.Curr Psychiatry Rep. 2012 Jun;14(3):211-9. doi: 10.1007/s11920-012-0268-9. Curr Psychiatry Rep. 2012. PMID: 22527872 Review.
-
A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder.Am J Psychiatry. 2008 May;165(5):621-30. doi: 10.1176/appi.ajp.2007.07091440. Epub 2008 Mar 3. Am J Psychiatry. 2008. PMID: 18316422 Free PMC article. Clinical Trial.
-
Defining cognitive-behavior therapy response and remission in pediatric OCD: a signal detection analysis of the Children's Yale-Brown Obsessive Compulsive Scale.Eur Child Adolesc Psychiatry. 2017 Jan;26(1):47-55. doi: 10.1007/s00787-016-0863-0. Epub 2016 May 21. Eur Child Adolesc Psychiatry. 2017. PMID: 27209422 Free PMC article. Clinical Trial.
-
The efficacy of brief strategic therapy in treating obsessive-compulsive disorder: a case series.Acta Biomed. 2022 Sep 22;93(S1):e2022271. doi: 10.23750/abm.v93iS1.13064. Acta Biomed. 2022. PMID: 36134720 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical